07:00 , Apr 30, 2015 |  BC Innovations  |  Tools & Techniques

Genentech's cell point

Researchers at Roche 's Genentech Inc. unit have put a stake in the ground on how they advocate tackling cell line authentication, with recommendations for a standardized naming system and a three-step method to verify...
08:00 , Dec 8, 2014 |  BioCentury  |  Emerging Company Profile

Eliminate, not recreate

TNF alpha inhibitors work well to suppress the inflammatory response in Crohn's disease, but only in one-third to one-half of patients. Enterome Bioscience S.A. is developing both a test to help physicians select the most...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Company News

Roche supply/service news

Roche said it will reduce headcount by 100 over the next three years in its high-throughput DNA sequencing 454 Life Sciences Corp. subsidiary before phasing out the subsidiary's product line in mid-2016. The pharma said...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

Roche sales and marketing update

Roche launched the GS GType TET2 /CBL/ KRAS and the GS GType RUNX1 Primer Sets worldwide for genetic variation detection in the TET2, casitas B cell lymphoma-b (Cbl-b) , K-Ras and runt-related transcription factor 1...
07:00 , Mar 15, 2012 |  BC Innovations  |  Cover Story

Keeping up with the nanopores

Speed and cost are the selling points for nanopore sequencing, which holds the promise of being faster than sequencing technologies currently on the market without needing extensive DNA sample preparation. But thus far speed has...
08:00 , Jan 30, 2012 |  BioCentury  |  Strategy

Roche re-sequences

Roche already has the broadest set of molecular diagnostic technologies in the industry, and the pharma hopes acquiring Illumina Inc. will give it access to the biggest potential growth area in the MDx space: whole...
07:00 , Sep 5, 2011 |  BC Week In Review  |  Clinical News

Hemoximer pyridoxalated hemoglobin polyoxyethylene: Interim Phase III data

Curacyte terminated the European Phase III PHOENIX trial after an interim analysis by an independent DMB showed a higher number of deaths in the PHP arm compared to the placebo arm. The DMB concluded that...
00:10 , Aug 30, 2011 |  BC Extra  |  Clinical News

Curacyte ends Phase III trial of shock candidate

Curacyte AG (Munich, Germany) terminated the European Phase III PHOENIX trial of distributive shock candidate hemoximer (pyridoxalated hemoglobin polyoxyethylene, or PHP) after an interim analysis showed a higher number of deaths in the treatment arm...
07:00 , Aug 29, 2011 |  BC Week In Review  |  Company News

Enzo management update

Enzo Biochem Inc. (NYSE:ENZ), Farmingdale, N.Y.   Business: Autoimmune, Infectious, Supply/Service   Hired: Kara Cannon as head of global marketing at Enzo's Enzo Life Sciences Inc. subsidiary, formerly VP diagnostics and biotechnology at Pall Corp....
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Roche management update

Roche (SIX:ROG: OTCQX:RHHBY), Basel, Switzerland   Business: Pharmaceuticals   Hired: Thomas Schinecker as president and lifecycle leader for sequencing at Roche's 454 Life Sciences Corp. subsidiary, effective Aug. 1, currently diagnostics general manager of Sweden...